Mark Agius

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 815 citations

Disease Management, Relapsing-remitting Multiple Sclerosis, Disease Progression +7

Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma

EUN‐KYU LEE, Ricardo A. Maselli, William G. Ellis et al. · Journal of Neurology Neurosurgery & Psychiatry · 1998 · 155 citations · Full text

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 137 citations · Full text

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 99 citations · Full text

Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia

Åse Mygland, Angela Vincent, John Newsom–Davis et al. · Archives of Neurology · 2000 · 95 citations